摘要
Abstract
Objective To analyze the application effect of Bevacizumab in the treatment of recurrent ovarian cancer.Methods From January 2021 to May 2024,100 patients with recurrent ovarian cancer were selected in the Department of Gynecology,the Affiliated Hospital of Guizhou Medical University.They were divided into bevacizumab group(50 cases,treated with conventional chemotherapy+Bevacizumab)and conventional chemotherapy group(50 cases,treated with conventional chemotherapy)according to the treatment method.The clinical efficacy,vascular endothelial growth factor(VEGF)level,tumor marker level(carcinoembryonic antigen[CEA],carbohydrate antigen 125[CA125],carbohydrate antigen 15-3[CA15-3],carbohydrate antigen 19-9[CA19-9]),immune cell level,toxic and side effect,and quality of life of the two groups were statistically analyzed.Results The total remission rate in the bevacizumab group was 82.00%,which was higher than 60.00%in the conventional chemotherapy group(P<0.05).After treatment,the levels of VEGF,CEA,CA125,CA15-3,CA19-9,DDX4,CD133 and CD4+CD25+in the bevacizumab group were lower than those in the conventional chemotherapy group,and the levels of CD3+,CD3+CD4+,CD4+/CD8+and NK cells were higher than those in the conventional chemotherapy group(P<0.05).The quality of life in the bevacizumab group was better than that in the conventional chemotherapy group(P<0.05).There was no difference in the total incidence of toxic and side effect between the two groups(P>0.05).Conclusion The application of Bevacizumab in the treatment of recurrent ovarian cancer is effective.关键词
复发性卵巢癌/贝伐珠单抗/肿瘤标志物/血管内皮生长因子/免疫细胞/毒副反应/生活质量Key words
Recurrent ovarian cancer/Bevacizumab/Tumor marker/Vascular endothelial growth factor/Immune cell/Toxic and side effect/Quality of life分类
医药卫生
